Company Overview of CureTech Ltd.
CureTech Ltd., a biotechnology company, develops immune modulating products for the treatment and control of cancer. Its products are antibodies and peptide-based vaccines that are designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner. It develops pidilizumab (CT-011), a humanized monoclonal antibody that interacts with PD-1, a B7 receptor-family-associated protein and exhibits anti-cancer immune response against a range of mouse and human tumors. The company was founded in 2001 and is based in Yavne, Israel.
42 Hayarkon Street
Founded in 2001
972 8 932 4000
972 8 932 4001
Key Executives for CureTech Ltd.
CureTech Ltd. Key Developments
Similar Private Companies By Industry
|BiogenCell Ltd.||Middle East/Africa|
|Kaiima Agro-Biotech Ltd.||Middle East/Africa|
|Nutrinia Ltd.||Middle East/Africa|
|Natural Compounds||Middle East/Africa|
Recent Private Companies Transactions
September 17, 2013
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Hyattsville, MD | University of Maryland University CollegePosted: Mar 26
- San Mateo, CA |Posted: Apr 05
- San Francisco, CA | Investment Firm Providing Private and Institutional BrokeragePosted: Apr 07
- Kansas City, MO | SkillsniperPosted: Apr 14
Sponsored Financial Commentaries
To contact CureTech Ltd., please visit www.curetechbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.